What "14.9% Mean Weight Loss" Actually Looks Like

If you've read about GLP-1 weight loss medications anywhere in the past two years, you've encountered the headline number: 14.9% mean body weight reduction at 68 weeks with semaglutide 2.4 mg. It comes from the STEP 1 trial, published in the New England Journal of Medicine in 2021. ¹

That number is real. But it tells you almost nothing about what to expect for yourself.

Here's the problem: 14.9% is a mean. It's the average of every patient who stayed in the trial, which means it averages together the people who lost 25% of their body weight with the people who lost almost nothing. If you treat that average as a forecast for your own outcome, you're going to be disappointed — or surprised — depending on which side of the distribution you fall on.

What the trial actually found

STEP 1 randomized 1,961 adults (mean baseline BMI 38) to semaglutide 2.4 mg weekly or placebo, both with lifestyle intervention. After 68 weeks, the semaglutide group lost an average of 14.9% of body weight, compared with 2.4% for placebo. ¹

But the response curve looked like this:

• Approximately 32% of semaglutide-treated patients lost 20% or more of body weight

• Approximately 50% lost between 10% and 20%

• Approximately 14% lost between 5% and 10%

• Approximately 4% lost less than 5% — or gained weight

So when a patient asks us "will I lose 15% of my body weight?", the honest answer is: maybe. The average person in the trial did. But you might be among the 32% who lose more, or the 18% who lose less than the headline number suggests. Distinguishing between those groups in advance is, mostly, not possible.

What predicts response?

Some signals are visible early. Patients who lose at least 5% of body weight in the first 12 weeks are statistically more likely to reach significant total loss. Conversely, patients with very limited response by week 16 — what we sometimes call early non-responders — are unlikely to catch up later. ²

Other predictors are less actionable. Higher starting BMI tends to associate with larger absolute weight loss. Female patients, on average, tend to respond slightly better than male patients in the trial data. ¹ Younger patients respond marginally better than older patients. None of these are definitive — they shift probabilities, not destinies.

The clinical implication: the first 16 weeks of treatment are diagnostic as much as therapeutic. If response is strong by week 12-16, the trajectory is established. If response is weak, that's actionable — dose escalation, evaluation of adherence, or switch to a different molecule (typically tirzepatide, which produced 20.9% mean loss at the 15 mg dose in SURMOUNT-1 ³).

Why "mean" is the wrong frame

Population means are how trials report results because they're statistically tractable. But they obscure something important: a 14.9% mean does not mean "everyone loses approximately 14.9%." It means the average of a wide distribution is 14.9%.

A more useful frame for an individual patient is the question: what's the probability I lose at least 10% of body weight? In STEP 1, that probability was approximately 82% for semaglutide patients, versus 26% for placebo. ¹ That's a meaningful number — and it's a number you can act on, because it tells you the rough odds of clinically meaningful response, not a hypothetical average that almost nobody hits exactly.

What this means for our concierge programs

When we publish "10–18% expected weight loss" for our GLP-1 Program , that range reflects the realistic distribution of outcomes — not the trial mean alone. The lower bound assumes a typical responder; the upper bound assumes a strong responder. The 32% of patients who exceed 20% loss are pleasant outliers we don't promise.

The 18% upper bound is also adjusted slightly downward from the SURMOUNT-1 maximum (20.9%) because our 6-8 month program is shorter than the 72-week SURMOUNT trial. Mean weight loss in trials continues to accumulate through approximately 60 weeks of treatment, then plateaus. ³ A 6-month program captures most — but not all — of the available weight loss curve.

The most useful question is not "will the average happen to me?" — but "what's the probability of clinically meaningful loss, and what early signals can my doctor and I watch for?"

The honest summary

If you're considering GLP-1 therapy, here's what the evidence actually supports:

• Most people on semaglutide 2.4 mg lose between 10% and 20% of body weight in the first year

• About one in three lose more; about one in five lose less

• Response is largely apparent by week 12-16 — early non-response often predicts overall non-response

• Tirzepatide tends to produce somewhat larger losses than semaglutide on average, with similar overall response distribution

• Maintaining the loss after stopping medication requires ongoing attention — and is a different question than reaching the loss in the first place

The "14.9% mean" headline is real, but it's a statistical summary, not a prediction. The clinical question — and the question worth asking your doctor — is what your individual response looks like in the first 12 weeks, and what the plan is if you fall on either tail of the distribution.

If you'd like to discuss whether GLP-1 therapy is appropriate for your situation, you can book a 45-minute consultation with one of our specialist physicians. We work through your medical history, lab markers, and goals — and recommend a path forward based on evidence, not averages.

Tagged
semaglutide bmi evidence-based

Medically reviewed
Siam Clinic Medical Team
All clinical claims verified against peer-reviewed sources. How we write & cite →

References

• Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

• Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4

• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038